These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 17016963)

  • 1. Safety monitoring in vaccine development and immunization.
    Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML
    Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.
    Niu MT; Ball R; Woo EJ; Burwen DR; Knippen M; Braun MM;
    Vaccine; 2009 Jan; 27(2):290-7. PubMed ID: 18992783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.
    Chang S; Ball R; Braun MM
    Vaccine; 2008 May; 26(19):2428-32. PubMed ID: 18406499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007.
    Haber P; Patel M; Izurieta HS; Baggs J; Gargiullo P; Weintraub E; Cortese M; Braun MM; Belongia EA; Miller E; Ball R; Iskander J; Parashar UD
    Pediatrics; 2008 Jun; 121(6):1206-12. PubMed ID: 18519491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination vaccines: postlicensure safety evaluation.
    Chen RT; Pool V; Takahashi H; Weniger BG; Patel B
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S327-33. PubMed ID: 11709768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines.
    Geier DA; Geier MR
    Brain Dev; 2004 Aug; 26(5):296-300. PubMed ID: 15165669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotavirus live, oral, pentavalent vaccine.
    Tom-Revzon C
    Clin Ther; 2007 Dec; 29(12):2724-37. PubMed ID: 18201590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
    LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
    Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System.
    Ball R; Braun MM; Mootrey GT;
    Clin Infect Dis; 2001 May; 32(9):1273-80. PubMed ID: 11303261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a national system for dealing with adverse events following immunization.
    Mehta U; Milstien JB; Duclos P; Folb PI
    Bull World Health Organ; 2000; 78(2):170-7. PubMed ID: 10743281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002.
    Begier EM; Burwen DR; Haber P; Ball R;
    Clin Infect Dis; 2004 Mar; 38(6):771-9. PubMed ID: 14999618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; West DJ;
    Pharmacoepidemiol Drug Saf; 2002; 11(3):189-202. PubMed ID: 12051118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety considerations for new vaccine development.
    Ellenberg SS
    Pharmacoepidemiol Drug Saf; 2001; 10(5):411-5. PubMed ID: 11802587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring vaccine safety during an influenza pandemic.
    Iskander J; Haber P; Herrera G
    Yale J Biol Med; 2005 Oct; 78(5):265-75. PubMed ID: 17132333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
    Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM
    Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Vaccine Safety Datalink project.
    DeStefano F;
    Pharmacoepidemiol Drug Saf; 2001; 10(5):403-6. PubMed ID: 11802585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System.
    Woo EJ; Burwen DR; Gatumu SN; Ball R;
    Clin Infect Dis; 2003 Aug; 37(3):351-8. PubMed ID: 12884159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.